Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
32 studies found for:    parp inhibitor ovarian | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Breast Cancer;   Malignant Female Reproductive System Neoplasm
Interventions: Drug: Olaparib;   Drug: AZD2014;   Drug: AZD5363
2 Recruiting A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Cediranib;   Drug: Olaparib
3 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Malignant Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Onalespib;   Other: Pharmacological Study
4 Recruiting Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasm
Interventions: Other: Placebo;   Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel
5 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Floxuridine;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
6 Recruiting A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Condition: Ovarian Cancer
Intervention: Drug: Niraparib
7 Recruiting PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Interventions: Drug: Olaparib;   Drug: Tremelimumab
8 Not yet recruiting Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: Platinum-based Chemotherapy
9 Recruiting Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Bevacizumab
10 Recruiting Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
Conditions: Lung Cancer;   Breast Cancer;   Ovarian Cancer;   Colorectal Cancer;   Prostate Cancer;   Triple Negative Breast Cancer
Interventions: Drug: Olaparib;   Drug: Cediranib;   Drug: MEDI4736
11 Not yet recruiting Response to PARP Inhibitor Predicted by the RAD51 Assay
Condition: Cancer
Intervention: Drug: Veliparib
12 Recruiting A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
Conditions: Ovarian Cancer;   Triple Negative Breast Cancer
Interventions: Drug: Fluzoparib;   Drug: Apatinib
13 Recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
14 Recruiting A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Conditions: Ovarian;   Breast;   SCLC;   Gastric Cancers
Interventions: Drug: Olaparib;   Drug: MEDI4736
15 Not yet recruiting Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Biological: Tremelimumab
16 Not yet recruiting Nivolumab in Prostate Cancer With Mutations in DNA Repair Defects (ImmunoProst Trial)
Condition: Prostate Cancer
Intervention: Drug: Nivolumab
17 Recruiting Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Conditions: Triple Negative Breast Cancer;   Ovarian Cancer;   Breast Cancer;   Metastatic Breast Cancer;   Advanced Breast Cancer;   Stage IV Breast Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: niraparib;   Biological: pembrolizumab
18 Recruiting A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Placebo
19 Available Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Condition: Ovarian Cancer
Intervention: Drug: Olaparib tablets
20 Recruiting ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Chemotherapy;   Drug: Rucaparib

   Previous Page Studies Shown (1-20) Next Page (21-32) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.